RE: Options Endo played their hand well.
For the refragtory patients, Urocidin might be their last chance before total resectionor death! Endo knows they can never find a good comparator based on their P3b experience unless they use BCG/ placebo. But that will make it a first line drug trial.
With the money shortage, BNC is desperate to get Urocidin into the market. They are willing to go first line. All Endo has to do is insist on testing Urocidin as a refractory drug. As long as they insist, Urocidin is dead.That forced BNC to "buy" the control back from them. So for not having to spend a cent more, they get a share of the future royalty. That's the ultimate blackmail. The best mafia move and a great business decision. Endo is not dumb.
And as a bonus, if BNC screwed up again at BNS's own cost, they get to protect the Valstar market.
GENIUS!